The Phase 3 clinical trial investigating fianlimab in combination with cemiplimab for patients with previously untreated unresectable locally advanced or metastatic melanoma reached its primary completion on 2026-03-12. This milestone indicates that data collection for the primary outcome measure has concluded, moving the study closer to potential results analysis.
Background
The study focuses on melanoma, a serious form of skin cancer. The trial evaluates an investigational combination therapy, fianlimab with cemiplimab, against pembrolizumab, which is an approved treatment for melanoma.
Trial design
The study, identified as NCT05352672, is a Phase 3 clinical trial. It enrolled 1546 adolescent and adult participants diagnosed with previously untreated unresectable locally advanced or metastatic melanoma. The trial compares the combination of fianlimab and cemiplimab against pembrolizumab, an established treatment for melanoma.
What this means
The primary completion of this Phase 3 trial for fianlimab in combination with cemiplimab marks a key step in the clinical development process. This stage indicates that all necessary data for the primary outcome has been collected. The next steps will involve data analysis and reporting, which will determine the efficacy and safety profile of the investigational combination therapy compared to pembrolizumab in patients with advanced melanoma.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05352672, titled "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma," was updated with a primary completion date of 2026-03-12 on clinicaltrials.gov.